What is MyBiosource?
MyBiosource operates as a critical infrastructure provider within the global life sciences ecosystem. By maintaining a vast catalog of over 2 million products, including high-precision ELISA kits, recombinant proteins, and specialized antibodies, the company serves as a primary procurement hub for academic and commercial research institutions. Their business model centers on the rapid delivery of molecular biology reagents, effectively bridging the gap between complex manufacturing and the immediate needs of researchers. By positioning itself as a one-stop shop for essential laboratory supplies, MyBiosource has successfully captured a significant share of the reagent market, particularly through its agility in supporting urgent research initiatives such as those related to COVID-19.
How much funding has MyBiosource raised?
MyBiosource has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in MyBiosource
PPP
Public-Private Partnership
What's next for MyBiosource?
Following this major strategic investment, MyBiosource is well-positioned to accelerate its operational expansion and deepen its market penetration. The influx of capital will likely be directed toward optimizing supply chain logistics and expanding the company's proprietary custom ELISA kit production capabilities. As the firm transitions through this late-stage growth phase, management is expected to focus on enhancing digital procurement interfaces and broadening its portfolio of recombinant proteins to meet the evolving demands of the biotechnology sector. By leveraging its existing infrastructure, MyBiosource aims to maintain its competitive edge, ensuring that researchers worldwide have consistent access to the high-quality reagents necessary for breakthrough scientific discovery.
See full MyBiosource company page
